Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy

Journal of Child Neurology

Volumn 25, Issue 11, 2010, Pages 1319-1324

  Matthews, Dennis J ^a   James, Katherine A ^b   Miller, Lisa A ^b   Pandya, Shree ^c   Campbell, Kimberly A ^d   Ciafaloni, Emma ^c   Mathews, Katherine D ^e   Miller, Timothy M ^f   Cunniff, Christopher ^f   Meaney, F John ^f   Druschel, Charlotte M ^d   Romitti, Paul A ^g   Fox, Deborah J ^d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Colorado Department of Public Health and Environment ^*  (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d New York Department of Health   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF IOWA   (United States)

Author keywords

Becker muscular dystrophy; corticosteroids; Duchenne muscular dystrophy; population based studies

Indexed keywords

DEFLAZACORT; PREDNISOLONE; PREDNISONE;

ARTICLE; BECKER MUSCULAR DYSTROPHY; BEHAVIOR DISORDER; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; UNITED STATES; WEIGHT GAIN;

EID: 78650186613     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073810362762     Document Type: Article

References (24)

1. Emery AE Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord. 1991 ; 1 (1). 19-29.
2. van Essen AJ, Verheij Jbgm, Reefhuis J., et al. The natural history of Duchenne muscular dystrophy: analysis of data from a Dutch survey and review of age related events. Online Leyden Muscular Dystrophy pages. 2004. http://www.dmd.nl/. Accessed May 10, 2009.
3. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974 ; 2 (7894). 1409-1412.
4. Fenichel GM, Brooke MH, Griggs RC, et al. Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E. Muscle Nerve. 1988 ; 11 (11). 1164-1168.
5. Mendell JR, Griggs RC, Moxley RT, et al. Clinical investigation in Duchenne muscular dystrophy: IV. Double-blind controlled trial of leonine. Muscle Nerve. 1984 ; 7 (7). 535-541.
6. Moxley RT III, Brooke MH, Fence GM, et al. Clinical investigation in Duchenne dystrophy: VI. Double-blind controlled trial of nifedipine. Muscle Nerve. 1987 ; 10 (1). 22-33.
7. Balaban B., Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005 ; 84 (11). 843-850.
8. Biggar WD Duchenne muscular dystrophy. Pediatr Rev. 2006 ; 27 (3). 83-88.
9. Biggar WD, Gingras M., Fehlings DL, Harris VA, Steele CA Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001 ; 138 (1). 45-50.
10. Biggar WD, Harris VA, Eliasoph L., Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006 ; 16 (4). 249-255.
11. Fenichel GM, Florence JM, Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991 ; 41 (12). 1874-1877.
12. King WM, Ruttencutter R., Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007 ; 68 (19). 1607-1613.
13. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol. 1987 ; 44 (8). 812-817.
14. Escolar DM, Scacheri CG Pharmacologic and genetic therapy for childhood muscular dystrophies. Curr Neurol Neurosci Rep. 2001 ; 1 (2). 168-174.
15. Wong BL, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol. 2002 ; 17 (3). 183-190.
16. van Essen AJ, Kneppers AL, van der Hout AH, et al. The clinical and molecular genetic approach to Duchenne and Becker muscular dystrophy: an updated protocol. J Med Genet. 1997 ; 34 (10). 805-812.
17. Yilmaz O., Karaduman A., Topaloglu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol. 2004 ; 11 (8). 541-544.
18. Moxley RT III, Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005 ; 64 (1). 13-20.
19. Griggs RC, Moxley RT III, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 1993 ; 43 (3 pt 1). 520-527.
20. Miller LA, Romitti PA, Cunniff C., et al. The Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res A Clin Mol Teratol. 2006 ; 76 (11). 793-797.
21. SAS Institute, Inc. SAS 9.1.3 Help and Documentation. Cary, NC: SAS Institute, Inc. ; 2000-2004.
22. Manzur AY, Kinali M., Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child. 2008 ; 93: 986-990.
23. Griggs RC, Moxley RT III, Mendell JR, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991 ; 48 (4). 383-388.
24. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 ; 320 (24). 1592-1597.